Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on January 27, 2009
JNCI Journal of the National Cancer Institute 2009 101(3):140-141; doi:10.1093/jnci/djn508
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/3/140    most recent
djn508v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schmidt, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

NEWS

Melanoma Vaccines: Possible Progress After Years of Frustration?

Charlie Schmidt

The first 150 words of the full text of this article appear below.

For decades, efforts to create a vaccine against melanoma, the most lethal type of skin cancer, have been exercises in frustration. As crafty as they are lethal, melanoma cells can mount evasive defenses that suppress a vaccine's intended role to shrink tumors. Because of that, just 3%–10% of patients treated with experimental vaccines typically show clinical improvements—and some of these may be spontaneous. But far from conceding defeat, scientists are intensifying their efforts to create better immunotherapies against melanoma, and those under development today show more promise than ever.

In a recent phase II clinical trial, Steven Rosenberg, M.D., Ph.D., chief of the National Cancer Institute's surgery branch, tested a new immunotherapy that shrank tumors in up to 72% of metastatic melanoma patients treated. This is the best "objective" result achieved yet in melanoma immunotherapy, according to Tom Gajewski, M.D., Ph.D., associate professor at the University of Chicago Medical Center. . . . [Full Text of this Article]

Treatment Versus Prevention

Beyond Traditional Approaches

Improving Vaccine Specificity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?